1.86 USD
+0.2 (+12.05%)
We assign a fundamental rating of 3 out of 10 to MNOV. MNOV was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MNOV as it has an excellent financial health rating, but there are worries on the profitability. MNOV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- MNOV had negative earnings in the past year.
- MNOV had a negative operating cash flow in the past year.
- In the past 5 years MNOV always reported negative net income.
- In the past 5 years MNOV always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -23.22%, MNOV is in the better half of the industry, outperforming 73.33% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -25.13%, MNOV is in the better half of the industry, outperforming 79.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.22% | ||
| ROE | -25.13% | ||
| ROIC | N/A |
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for MNOV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
- MNOV has about the same amout of shares outstanding than it did 1 year ago.
- MNOV has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of 0.56, we must say that MNOV is in the distress zone and has some risk of bankruptcy.
- With a decent Altman-Z score value of 0.56, MNOV is doing good in the industry, outperforming 62.29% of the companies in the same industry.
- MNOV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.56 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- MNOV has a Current Ratio of 9.86. This indicates that MNOV is financially healthy and has no problem in meeting its short term obligations.
- MNOV has a Current ratio of 9.86. This is amongst the best in the industry. MNOV outperforms 80.38% of its industry peers.
- A Quick Ratio of 9.86 indicates that MNOV has no problem at all paying its short term obligations.
- MNOV has a better Quick ratio (9.86) than 80.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.86 | ||
| Quick Ratio | 9.86 |
3. Growth
3.1 Past
- MNOV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.05%.
- MNOV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 11.64% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-77.39%
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MNOV. In the last year negative earnings were reported.
- Also next year MNOV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as MNOV's earnings are expected to decrease with -21.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
5. Dividend
5.1 Amount
- No dividends for MNOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MEDICINOVA INC / MNOV FAQ
What is the ChartMill fundamental rating of MEDICINOVA INC (MNOV) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MNOV.
What is the valuation status of MEDICINOVA INC (MNOV) stock?
ChartMill assigns a valuation rating of 0 / 10 to MEDICINOVA INC (MNOV). This can be considered as Overvalued.
Can you provide the profitability details for MEDICINOVA INC?
MEDICINOVA INC (MNOV) has a profitability rating of 1 / 10.
How financially healthy is MEDICINOVA INC?
The financial health rating of MEDICINOVA INC (MNOV) is 7 / 10.
What is the earnings growth outlook for MEDICINOVA INC?
The Earnings per Share (EPS) of MEDICINOVA INC (MNOV) is expected to decline by -77.39% in the next year.